|
Clinical narrative:
an impella rp flex device was inserted into the right internal jugular vein in a 33-year-old female patient presenting in right heart failure due to cardiomyopathy secondary to myocarditis.Prior to impella support, the patient was classified as society for cardiovascular angiography & interventions (scai) stage e shock, indicating that the body was failing to respond to maximal life-saving therapies, leading to full organ shutdown.The patient was receiving multiple inotropes and vasopressors and ventilatory support.The patient's past medical history includes coronary artery disease (cad).The impella rp flex was inserted for right ventricular support as part of bipella therapy in conjunction with an impella cp.Upon transfer to a new facility on day 1 of support, gross hemolysis was reported along with ¿placement signal low¿ alarms.Bedside point-of-care ultrasound (pocus) was performed, and the impella rp flex was retracted approximately 5 cm.Following repositioning, the device waveforms improved.A formal echocardiogram was planned for further evaluation.Despite repositioning, the reported hemolysis did not resolve.No plasma-free hemoglobin and lactate dehydrogenase (ldh) values were reported.After approximately 20 hours of support, the impella rp flex was removed, and the patient remained on impella cp support.No adverse clinical consequences were reported.Throughout support, the impella rp flex functioned within expected operating parameters at performance level p-8 with reported flows of approximately 3.2 l/min utilizing a d5w sodium bicarbonate purge solution.The post-procedure outcome is survived at explant.Based on the available information, the reported hemolysis may have been associated with suboptimal impella rp flex positioning.Despite repositioning, hemolysis persisted, suggesting that additional patient-specific factors may have contributed, including severe right heart failure, myocarditis, and the use of multiple mechanical circulatory support devices, which is associated with an increased risk of shear stress on red blood cells.
|
|
This report is being submitted pursuant to the provisions of 21 cfr, part 803.This report may be based on information which has not been investigated or verified prior to the required reporting date.This report does not reflect a conclusion by abiomed inc, or its employees that the report constitutes an admission that the product, abiomed inc, or its employees caused or contributed to the potential event described in this report.If information is obtained that was not available for the initial report, a follow-up report will be filed as appropriate.
|